147 related articles for article (PubMed ID: 38110467)
1. Lymphocyte subsets and inflammatory factors as predictors of immunotherapy efficacy in patients with hepatocellular carcinoma.
Shuyue G; Jiamin C; Niansong Q
Sci Rep; 2023 Dec; 13(1):22480. PubMed ID: 38110467
[TBL] [Abstract][Full Text] [Related]
2. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
3. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
4. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
5. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract][Full Text] [Related]
6. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
8. [Application of TIGIT combined with interleukin-6 detection in the evaluation of Crohn's disease status].
Xiao L; Yang JP; Wang W
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Aug; 57(8):1253-1258. PubMed ID: 37574320
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
Wang Z; Weiner GJ
J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
[TBL] [Abstract][Full Text] [Related]
10. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma.
Li Z; Li N; Li F; Zhou Z; Sang J; Jin Z; Liu H; Han Q; Lv Y; Liu Z
Oncotarget; 2016 May; 7(18):26168-80. PubMed ID: 27034168
[TBL] [Abstract][Full Text] [Related]
13. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
Kim KJ; Lee HW; Seong J
J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056
[TBL] [Abstract][Full Text] [Related]
15. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
16. Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells.
Martín-Manzo MV; Lara C; Vargas-de-Leon C; Carrero J; Queipo G; Fonseca-Sanchez M; Mejia-Dominguez NR; Kershenobich D; Mummidi S; Zentella-Dehesa A; Hernandez J
Pathol Oncol Res; 2019 Jul; 25(3):1233-1243. PubMed ID: 30759303
[TBL] [Abstract][Full Text] [Related]
17. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
Wang P; Chen Y; Long Q; Li Q; Tian J; Liu T; Wu Y; Ding Z
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625514
[TBL] [Abstract][Full Text] [Related]
18. Persistent lymphocyte reduction and interleukin-6 levels are independently associated with death in patients with COVID-19.
Xu Y; Wang N; Shen X; Liu X; Liu H; Liu Y
Clin Exp Med; 2023 Nov; 23(7):3719-3728. PubMed ID: 37310657
[TBL] [Abstract][Full Text] [Related]
19. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients.
Machiraju D; Wiecken M; Lang N; Hülsmeyer I; Roth J; Schank TE; Eurich R; Halama N; Enk A; Hassel JC
Oncoimmunology; 2021 May; 10(1):1926762. PubMed ID: 34104542
[TBL] [Abstract][Full Text] [Related]
20. Genetic association and interaction of PD1 and TIM3 polymorphisms in susceptibility of chronic hepatitis B virus infection and hepatocarcinogenesis.
Li F; Fan X; Wang X; Deng H; Zhang X; Zhang K; Li N; Han Q; Lv Y; Liu Z
Discov Med; 2019 Feb; 27(147):79-92. PubMed ID: 30939292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]